BridgeBio director sells 5,004 shares in Form 4
BridgeBio Pharma director Hannah Valantine reported several equity transactions in the company’s stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma director Hannah Valantine reported several equity transactions in the company’s stock. She sold 2,808 shares of Common Stock at $68.00 per share and 2,196 shares at $68.57 per share in open‑market sales executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on November 14, 2025.
On the same date, she exercised stock options to acquire 2,808 shares at an exercise price of $41.73 per share and received a grant of 3,990 restricted stock units that will vest in full on June 22, 2027, each representing one share of Common Stock. Following these transactions, she holds 9,259 shares directly and 398 shares indirectly through her spouse.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Valantine Hannah
Role
Director
Sold
5,004 shs ($342K)
Approx. gross sale proceeds
$342K
Approx. exercise cost
$117K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,196 | $68.57 | $151K |
| Grant/Award | Stock Option (Right to Buy) | 5,277 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 2,808 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,990 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,808 | $41.73 | $117K |
| Sale | Common Stock | 2,808 | $68.00 | $191K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,894 contracts (Direct);
Common Stock — 9,259 shares (Direct);
Common Stock — 398 shares (Indirect, By Spouse)
Footnotes (5)
- F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
- F4. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F5. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
Key Figures
Shares sold at $68.00: 2,808 shares
Shares sold at $68.57: 2,196 shares
Options exercised: 2,808 shares at $41.73/share
+4 more
7 metrics
Shares sold at $68.00
2,808 shares
Open-market sale of Common Stock at $68.00 per share
Shares sold at $68.57
2,196 shares
Open-market sale of Common Stock at $68.57 per share
Options exercised
2,808 shares at $41.73/share
Exercise of stock options into Common Stock
RSUs granted
3,990 RSUs
Vest in full on June 22, 2027, one share per RSU
New stock option grant
5,277 shares at $68.92
Stock option with expiration on June 21, 2036
Direct holdings after transactions
9,259 shares
Common Stock held directly by the reporting person
Indirect holdings by spouse
398 shares
Common Stock reported as owned "By Spouse"
Key Terms
Rule 10b5-1 sales plan, restricted stock units ("RSUs"), Stock Option (Right to Buy), vest in full, +1 more
5 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025."
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vest in full financial
"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service"
beneficial ownership financial
"398.0000, direct_or_indirect: I, nature_of_ownership: By Spouse"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BridgeBio (BBIO) director Hannah Valantine do in this Form 4?
Director Hannah Valantine reported selling 5,004 shares of BridgeBio Common Stock in open‑market transactions and also reported equity awards and an option exercise. The filing shows both sales activity and new grants affecting her overall ownership position.
Were Hannah Valantine’s BridgeBio (BBIO) stock sales pre-planned?
Yes. A footnote states the sales were effected under a Rule 10b5‑1 sales plan adopted on November 14, 2025. Such plans are pre‑arranged trading programs that allow insiders to sell shares on a scheduled basis regardless of later information.
What new equity awards did Hannah Valantine receive from BridgeBio (BBIO)?
She received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, subject to continued board service. Each RSU represents a contingent right to receive one share of Common Stock if the vesting condition is satisfied.
What stock options did Hannah Valantine exercise or receive in this BridgeBio (BBIO) filing?
She exercised options for 2,808 shares of Common Stock at an exercise price of $41.73 per share. She was also granted a new stock option for 5,277 shares with a conversion or exercise price of $68.92, expiring on June 21, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates